Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing–remitting multiple sclerosis by Cramer, Stig P. et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Permeability of the blood–brain barrier predicts no evidence of disease activity at 2
years after natalizumab or fingolimod treatment in relapsing–remitting multiple
sclerosis
Cramer, Stig P.; Simonsen, Helle J.; Varatharaj, Aravinthan; Galea, Ian; Frederiksen, Jette L.;
Larsson, Henrik B.W.
Published in:
Annals of Neurology
DOI:
10.1002/ana.25219
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Cramer, S. P., Simonsen, H. J., Varatharaj, A., Galea, I., Frederiksen, J. L., & Larsson, H. B. W. (2018).
Permeability of the blood–brain barrier predicts no evidence of disease activity at 2 years after natalizumab or
fingolimod treatment in relapsing–remitting multiple sclerosis. Annals of Neurology, 83(5), 902-914.
https://doi.org/10.1002/ana.25219
Download date: 03. Feb. 2020
RESEARCH ARTICLE
Permeability of the Blood–Brain Barrier
Predicts No Evidence of Disease Activity
at 2 Years after Natalizumab or
Fingolimod Treatment in Relapsing–
Remitting Multiple Sclerosis
Stig P. Cramer, MD, PhD,1 Helle J. Simonsen, BMS,1
Aravinthan Varatharaj, BMBCh,2 Ian Galea, MD, PhD,2
Jette L. Frederiksen, MD, DMSc,3,4 and Henrik B. W. Larsson, MD, DMSc1,4
Objective: To investigate whether blood–brain barrier (BBB) permeability, as measured by dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI), can provide early detection of suboptimal treatment response in
relapsing–remitting multiple sclerosis (RRMS).
Methods: Thirty-five RRMS patients starting on fingolimod or natalizumab, drugs with a common effect of decreas-
ing lymphocyte influx into the central nervous system, were scanned with DCE-MRI at 3T prior to treatment and at 3
and 6 months posttreatment. We calculated the influx constant Ki, a measure of BBB permeability, using the Patlak
model. Suboptimal treatment response was defined as loss of no evidence of disease activity (NEDA) status after 2
years of treatment.
Results: Subjects with loss of NEDA status at 2 years had a 51% higher mean Ki in normal-appearing white matter
(NAWM) measured after 6 months of treatment, compared to subjects with maintained NEDA status (mean differen-
ce5 0.06ml/100g/min, 95% confidence interval [CI]5 0.02–0.09, p50.002). Ki in NAWM at 6 months was a good
predictor of loss of NEDA status at 2 years (area under the curve5 0.84, 95% CI5 0.70–0.99, p50.003), and a value
above 0.136ml/100/g/min yielded an odds ratio of 12.4 for suboptimal treatment response at 2 years, with a sensitiv-
ity of 73% and a specificity of 82%.
Interpretation: Our results suggest that BBB permeability as measured by DCE-MRI reliably predicts suboptimal
treatment response and is a surrogate marker of the state of health of the BBB. We find a predictive threshold for
disease activity, which is remarkably identical in clinically isolated syndrome as previously reported and established
RRMS as investigated here.
ANN NEUROL 2018;83:902–914
A large number of immunomodulatory disease-modifying therapies (DMTs) are now available for
relapsing–remitting multiple sclerosis (RRMS). Their main
objective is a reduction in the number and severity of relap-
ses, occurrence of new or enlarging lesions on magnetic res-
onance imaging (MRI), and prevention or delay in the
onset of secondary progressive disease. In European coun-
tries, natalizumab and fingolimod share the same indication
as second-line therapies in highly active RRMS, or as first-
line therapy for aggressive and rapidly evolving disease.1
Natalizumab is a monoclonal antibody against the a4b1
integrin receptor, which mediates lymphocyte adherence to
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the endothelium, thereby directly suppressing lymphocyte
passage across the blood–brain barrier (BBB).2 Fingolimod
is an agonist of the sphingosine-1 receptor, inducing recep-
tor internalization and thereby trapping encephalitogenic
lymphocytes in lymph nodes,3 preventing them from
migrating into the central nervous system. Hence, although
the mechanism of action of these two drugs is different,
their final effect is the same, that is, a reduction of the abso-
lute number of lymphocytes trafficking across the BBB, as
demonstrated by an equivalent reduction in CD4 lympho-
cyte counts in the cerebrospinal fluid (CSF).4 Both treat-
ments have been shown to be highly efficacious in reducing
relapse rates by 54 to 68%, reducing occurrence of new T2
lesions on MRI as well as the number of visibly contrast-
enhancing lesions.5–7 Despite the high overall efficacy, the
treatment response is highly heterogeneous, and a subset of
patients still experience disease activity.8 To evaluate treat-
ment response, the concept of no evidence of disease activity
(NEDA), which uses a zero-tolerance threshold (no signs of
disease activity in any of 3 domains) has been proposed as a
treatment goal.9–11 Evaluating NEDA status after 2 years of
DMTmay be a reasonable approach, because it holds a pos-
itive predictive value of 78.3% for no progression at 7 years,
with only minor improvement for re-evaluation at years 3
to 5.11 However, early detection of suboptimal treatment
response is becoming increasingly important, both in the
context of the increasing number of available therapies5,12,13
and due to DMTs seeming to have their best effect in the
early stages of disease,14 but no current method or clinical
variable exists that is able to perform such stratification.8,15
We have previously reported that BBB permeability in mul-
tiple sclerosis (MS) normal-appearing white matter
(NAWM), measured as the influx constant Ki by dynamic-
contrast enhanced MRI (DCE-MRI), is abnormal when
compared to controls, is a marker of recent clinical relapse
activity, and is attenuated by disease-modifying treatment.16
Ki in NAWM correlates with biomarkers of immune cell
trafficking in the CSF, and predicts conversion from optic
neuritis to MS 2 years after onset.17 Hence, we hypothesize
that Ki can stratify MS patients according to DMTresponse,
here defined as loss of NEDA status at 1 and 2 years of
second-line treatment. Furthermore, we aim to characterize
the mechanistic relationship between Ki and cellular traffic,
in the setting of treatments whose common end result is a
reduction in lymphocyte traffic across the BBB.
Patients and Methods
Study Participants
We prospectively included all RRMS patients referred for MRI
by the MS clinic at Rigshospitalet, Glostrup between August
2011 and November 2013 as part of an evaluation prior to ini-
tiation of natalizumab or fingolimod treatment. Inclusion
criteria were: (1) an established diagnosis of MS, (2) clinical
indication for treatment with either natalizumab or fingolimod,
and (3) age5 18 to 59 years. Exclusion criteria were: (1) other
concurring disease and (2) contraindication to MRI scan or
MRI contrast agent. Eighty-five RRMS patients were assessed
for eligibility, of whom 45 patients met the inclusion criteria
and agreed to participate in a baseline scan (Fig 1). Thirty-five
of these proceeded to initiation of either natalizumab or fingoli-
mod, all of whom had a follow-up MRI performed at 3
months posttreatment. Twenty-nine patients participated in the
6-month posttreatment MRI. After study completion, 2 sub-
jects were excluded, the first due to the occurrence of antinatali-
zumab antibodies, which resulted in treatment cessation after 5
months of treatment, and the second due to suspected side
effects to fingolimod in the form of macular edema, which
resulted in treatment cessation after 8 months. Follow-up MRI
scans were performed as close as possible to the 3-month
(mean5 97 days, standard deviation [SD]5 13 days) and 6-
month time points (mean5 189 days, SD5 17 days) posttreat-
ment using the therapy initiation day as reference and consisted
of axial T2, axial fluid-attenuated inversion recovery (FLAIR),
and axial postcontrast T1 of the cerebrum as well as DCE-MRI
(see below for sequence parameters). Spinal cord assessment was
performed at baseline, but not at the 3- and 6-month follow-
up scans. We recorded any use of methylprednisolone during
the course of the study, with the intention to postpone any 3-
or 6-month follow-up scan by 2 months after completion of
steroid treatment. Only 1 subject was treated with intravenous
FIGURE 1: Subject inclusion procedure. MRI5magnetic res-
onance imaging. [Color figure can be viewed at www.annal-
sofneurology.org]
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methylprednisolone during the first 6 months of the study.
This occurred 4 months after treatment initiation, due to a
major relapse 65 days before the planned 6-month scan, obviat-
ing the need for postponing the scan. Clinical data were
obtained from hospital records 2 years after second-line treat-
ment initiation for each individual subject. Collected variables
were: baseline MS disease duration, baseline treatment status,
history of methylprednisolone use, clinical relapses 12 months
prior to second-line treatment initiation, and number of relap-
ses, MRI activity, and Expanded Disability Status Scale (EDSS)
at 1 and 2 years after treatment initiation. All subjects had reg-
ular clinical follow-up visits 3, 6, 12, 18, and 24 months post-
treatment as part of standard clinical practice. Antinatalizumab
antibodies were measured at 3, 6, 9, and 12 months. Collection
of clinical data was performed by an experienced MS clinician
who was blinded to the DCE-MRI results (another researcher
analyzed the MRI data). Subjects who missed a clinical visit or
an MRI were treated as missing data for the purpose of statisti-
cal analysis. Only subjects who completed a full 1 or 2 years of
treatment were included in the 1- and 2-year analyses.
Outcome Measures
We used the following definitions. Relapse was defined as the
appearance of new neurological symptoms or signs that lasted
>24 hours in the absence of concurrent fever or illness.18 The
treating physician recorded relapses at the face-to-face visits at
3, 6, 12, 18, and 24 months. Progression was defined as an
EDSS score increase of 1 or more points recorded at a biannual
clinical visit that was sustained at the subsequent clinical visit 6
months later.11,19 If the EDSS score was zero at baseline, pro-
gression was defined as an EDSS score change of 1.5 or more
that was sustained at the subsequent clinical visit.11 MRI activity
was defined as new or enlarging T2 hyperintense lesions or T1
gadolinium-enhancing lesions in brain or spinal cord. To qual-
ify as no evidence of MRI activity, new T2 hyperintense lesions
and T1 gadolinium-enhancing lesions had to be absent on
brain and spinal cord MRI. As recently suggested, disease activ-
ity occurring within the first 3 months after initiation of natali-
zumab or fingolimod treatment was disregarded when assessing
NEDA status, to allow for development of a full treatment
effect.10,20 The earliest occurring loss of NEDA events within
the 3 NEDA subdomains were (1) a new T2 lesion at 6 months
(this subject had another new T2 lesion at 1 year thus also ful-
filling loss of NEDA at 12 months), (2) a relapse at 7 months,
and (3) an EDSS increase at 1 year. Thus, loss of NEDA status
did not occur prior to the 6-month MRI scan.
Ethics
This study was approved by the Ethics Committee of Copenha-
gen County according to the standards of the National Com-
mittee on Health Research Ethics, protocol number H-D-2008-
002. All experiments were conducted in accordance with the
Helsinki Declaration of 1975, and all subjects gave written
informed consent.
DCE-MRI
MRI was performed on a 3T magnetic resonance unit (Achieva;
Philips, Best, the Netherlands) using a 32-element phased-array
head coil. DCE-MRI used a T1-weighted saturation-recovery
gradient-echo sequence with flip angle5 30 8, repetition time-
5 3.9 milliseconds, echo time5 1.9 milliseconds, centric phase
ordering, parallel imaging factor5 2, acquired matrix5 963 61,
acquired voxel size5 2.403 2.983 8mm3 (interpolated to
0.903 0.893 8mm3), field of view5 2303 182mm2, 5 slices,
slice thickness5 8mm. Data for an initial measurement of relaxa-
tion time (T1) and equilibrium magnetization (M0) were gener-
ated using a series of saturation time delays from 120 milliseconds
to 10 seconds, covering the same slices as imaged during the bolus
passage. The dynamic sequence used a saturation time delay of
120 milliseconds, giving a time resolution of 1.25 seconds, and
750 time points, corresponding to a total sampling duration of
15.7 minutes. The automatic bolus injection (Spectris; MedRad,
Warrendale, PA) with speed 3ml/s followed by 20ml saline was
started after the 10th time point. The dose of contrast agent (gado-
butrol 1mmol/ml) was 0.045mmol/kg body weight. We acquired
a separate slice at the level of the internal carotid artery to obtain
an arterial input function with minimal partial volume for every
subject. The remaining 4 DCE slices were used for defining
regions of interest (ROIs) and subsequent estimation of tissue
pharmacokinetic values. To achieve a full clinical dose of gadobu-
trol (0.1ml/kg), which is important for adequate detection of visi-
bly contrast-enhancing lesions,21 we injected the remaining
contrast agent after the DCE acquisition and waited 5 minutes
before acquiring the postcontrast T1 sequence.
MRI Sequences and ROIs
We used an axial T2-weighted MRI sequence (5 slices, echo
time5 100 milliseconds, repetition time5 3,000 milliseconds,
acquired voxel size5 0.573 0.763 8mm3 [interpolated to
0.453 0.453 8mm3], field of view5 2303 119mm2) with same
orientation and slice thickness (8mm) as our DCE-MRI sequence,
to manually draw ROIs in the periventricular NAWM, and in the
normal-appearing thalamic gray matter in both hemispheres, avoid-
ing inclusion of, or proximity to, any MS lesions or diffusely abnor-
mal white matter, as previously described in detail.16 Four ROIs
were placed in periventricular NAWM (2 in the vicinity of the fron-
tal ventricular horns [1 in each hemisphere] and 2 in the vicinity of
the posterior horn [1 in each hemisphere]). Examples of ROI place-
ment on anatomical images and corresponding Ki maps from 2 sub-
jects can be seen in Figure 2. T2 lesions counts were performed by
an experienced neuroradiologist using an axial T2 FLAIR sequence
(35 slices, echo time5 125 milliseconds, repetition time5 11,000
milliseconds, acquired voxel size5 0.653 0.993 3.5mm3 [interpo-
lated to 0.453 0.453 3.5mm3], field of view5 2303 119mm2,
slice thickness5 3.5mm). ROIs were placed a minimum of 10mm
from any MS lesion or CSF-containing structures. In the presence of
contrast-enhancing lesions on a postcontrast axial T1-weighted
spin echo sequence (44 slices, echo time5 10 milliseconds, repeti-
tion time5 600 milliseconds, acquired voxel size5 0.943 1.25
3 3mm3 [interpolated to 0.943 0.943 3mm3], field of view
5 2403 240mm2, slice thickness5 3mm), we took care not to
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include the nearest 30mm of nonenhancing tissue. Our 4 DCE slices
were placed with exactly the same angulation and anatomical posi-
tion as the previous scan (evaluated for every scan). We ensured con-
sistent positioning and size of our ROIs across different study time
points by visual alignment with the previous scan.
Permeability Estimation
The DCE-MRI data were analyzed with a semiautomated pro-
cedure22 using in-house MATLAB-based software. The DCE
time series was converted to units of contrast agent concentra-
tion using T1 and M0, as determined from the multiple
FIGURE 2: Arterial input function in arbitrary signal units (A, left) and concentration (A, right), and region of interest placement.
Examples from 2 subjects are shown: left column from a subject with maintained no evidence of disease activity (NEDA) status
after 2 years of treatment (A1, B1, C1, and D1) and right column from a subject with loss of NEDA status after 2 years of treat-
ment (A2, B2, C2, and D2). Region of interest placement represents 2 examples in normal-appearing white matter (B, C) and 1
in thalamus (D) with their corresponding Patlak plots at 6 months posttreatment. a.u.5 arbitrary units; MR5magnetic reso-
nance; ROI5 region of interest; SD5 standard deviation. [Color figure can be viewed at www.annalsofneurology.org]
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saturation delay data, and a contrast agent relaxivity of 4s21/
mM21. The input function was measured in the voxel of the
internal carotid artery with maximal signal change during the
bolus passage and was corrected for partial volume by normaliz-
ing to a magnitude- and phase-derived venous outflow func-
tion, sampled in the sagittal sinus23 ad modum Van Osch.24
The median signal–time curve for all voxels in the ROI was
extracted and used to calculate permeability. For each tissue
type, we used the median value of permeability to exclude
effects of possible outliers (eg, 4 regions of NAWM were
drawn, of which the median was used to represent NAWM).
Every subject was represented by 1 value calculated as a mean
of the tissue-specific ROIs, as previously described.16,17,25 Tis-
sue concentration–time curves were evaluated using a combina-
tion of model-free deconvolution and a Patlak model, as
described in previous work.26 Permeability values, measured as
Ki (full blood), relate to K
trans (plasma) by Ki5K
trans/(1 2
Hct). A fixed value of Hct5 0.45 was used throughout the
study. Values of Ki are reported as ml/100g/min, assuming
brain tissue density of 1g/ml.27
Statistics
Histograms, probability plots, and modified Kolmogorov–Smir-
nov (Lilliefors) testing were used to analyze continuous variables
for standard normal distribution fit.28,29 If the data were found
to follow a normal distribution, 2-tailed Student t tests were
used. If not, first a logarithmic transformation of the data was
performed, and if normal distribution was not achieved, a
Mann–Whitney U test was used. For comparisons between cat-
egorical data, chi-square tests were performed. We used a multi-
ple linear regression approach to model the relationship
between baseline Ki and MS clinical parameters. A 1-way
repeated measures analysis of variance (ANOVA) was used to
test for time effects after initiation of second-line treatment.
Receiver operating characteristic (ROC) curves were used to
estimate the predictive capability (area under the curve [AUC],
and threshold with optimal sensitivity and specificity) of Ki to
predict suboptimal treatment response, defined as loss of
NEDA status. Logistic regression was performed to test for
effects of multiple continuous independent variables on loss of
NEDA status, and linear discriminant analysis was used when
there were >2 possible outcomes. A p value< 0.05 allowed
rejection of the null hypothesis. All analyses were performed in
SPSS version 23 (IBM, Armonk, NY).
MULTIPLE COMPARISONS. The a priori hypothesis was that
Ki after treatment initiation predicts suboptimal treatment
effect, and we have thus investigated the performance of 4 dif-
ferent variables (Ki in NAWM and thalamus at 3 and 6
months). Applying a Bonferroni correction but taking the cor-
relation coefficient (CC; average CC5 0.49) between the mea-
sured variables into account by way of the Dubey–Armitage-
Parmar approach,30,31 the threshold for rejecting the null
hypothesis becomes p5 0.024. All p values are thus reported
uncorrected, but only described as significant if falling below
p5 0.024.
Results
Baseline Data
Univariate linear regression analysis showed that baseline
permeability in NAWM was predicted by methylprednis-
olone treatment 2 months prior (b520.50, p5 0.003),
but not by days since last relapse (p5 0.38), first-line
treatment (yes/no; p5 0.53), or visibly contrast-
enhancing lesions (whether entered as yes/no [p5 0.70]
or actual count [p5 0.68]). In multivariate analysis,
methylprednisolone treatment 2 months prior
(b520.71, p5 0.00008) and days since last relapse
(b520.48, p5 0.005) predicted baseline Ki in NAWM
(model R25 0.40, p5 0.0002), but not first-line treat-
ment (yes/no; p5 0.55) or visibly contrast-enhancing
lesions (p5 0.76). In thalamus, baseline Ki was predicted
by methylprednisolone treatment 2 months prior to base-
line (b520.45, p5 0.01), but not by days since last
relapse (p5 0.58) in univariate analysis. Baseline perme-
ability according to current treatment and recent relapse
can be seen in Figure 3.
FIGURE 3: Baseline permeability in normal-appearing white
matter (NAWM) for all subjects with a baseline scan
(n545) according to current treatment and recent relapse.
SPSS 23 standard setup for boxplot presentation was
used. Black lines represent the median. Boxes represent
the interquartile range (IQR; data between the 25% and
75% quartiles). Whiskers represent 1.5 times the IQR. Out-
liers (open circles) are defined as data points outside
1.53 IQR. One subject was treated with pulsed steroids
(50mg every first 3 days/month), and thus received methyl-
prednisolone treatment despite not having had a recent
relapse. GA5glatiramer acetate; IFN-Beta5 interferon
beta. [Color figure can be viewed at www.annalsofneurol-
ogy.org]
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Treatment Effect
Between subjects receiving natalizumab and fingolimod
there was no difference in mean Ki pretreatment (NAWM:
mean difference5 0.008ml/100g/min, 95% confidence
interval [CI]520.05 to 0.06, p5 0.78; thalamus: mean
difference5 0.01ml/100g/min, 95% CI520.04 to 0.06;
p5 0.65) and 6 months posttreatment (NAWM: mean
difference5 0.004ml/100g/min, 95% CI520.04 to
0.05, p5 0.84; thalamus: mean difference5 0.0002ml/
100g/min, 95% CI520.05 to 0.05, p5 0.99). However,
at 3 months posttreatment, Ki in NAWM (mean differen-
ce5 0.06ml/100g/min, 95% CI5 0.02–0.10, p5 0.002)
and thalamus (mean difference5 0.04ml/100g/min, 95%
CI5 0.01–0.08, p5 0.011; both Student t tests) was
higher in the natalizumab-treated patients, possibly reflect-
ing a clinical selection bias favoring treatment of patients
with highly active disease with natalizumab, as previously
seen.32,33 Of natalizumab-treated subjects, 3 of 11 had a
relapse during the first 6 months of treatment (occurring
7, 8, and 133 days posttreatment) as opposed to 1 of 24
fingolimod-treated subjects (occurring 20 days posttreat-
ment), possibly reflecting the same bias. A 1-way repeated
measures ANOVA analysis with Ki in NAWM pretreat-
ment and 6 months posttreatment as outcome and baseline
methylprednisolone, days since last relapse, and first-line
treatment as covariates found no significant effect of time
(p5 0.079), but the interaction between time and baseline
methylprednisolone showed a trend (p5 0.041; Fig 4).
Significant between-subject covariates were baseline meth-
ylprednisolone treatment (p5 0.001) and days since last
relapse (p5 0.021).
No Evidence of Disease Activity
After 1 year of second-line treatment, 12 of 35 subjects
(34%) lost NEDA status. After 2 years, this increased to 15
of 35 (43%). Five of 11 (45%) natalizumab-treated subjects
and 10 of 24 (42%) fingolimod-treated subjects had lost
NEDA status at 2 years. Of the 15 subjects who lost NEDA
status at 2 years, 4 subjects had activity in all 3 NEDA sub-
domains (relapse[s], new MRI activity, and EDDS increase),
3 subjects had relapse(s) and EDSS increase, 1 subject had
new MRI activity and EDSS increase, 4 subjects had relap-
se(s) only, 2 subjects had EDSS increase only, and 1 subject
had MRI activity only. Baseline demographics, clinical char-
acteristics, and Ki values according to NEDA status at 2 years
are shown in Table 1. Three subjects experienced a relapse
shortly after starting treatment (7, 8, and 20 days after treat-
ment initiation), but per protocol these were disregarded.
Subjects who lost NEDA status at 2 years had a 51% higher
Ki in NAWM at 6 months posttreatment (mean differen-
ce5 0.06ml/100g/min, 95% CI5 0.02–0.09, p5 0.002)
and a 78% higher annual relapse rate (ARR) 1 year pretreat-
ment (mean difference5 0.93, 95% CI5 0.38–1.5,
p5 0.002; all Student t tests), when compared to subjects
who maintained NEDA status (see Table 1 and Fig 5). Ki at
baseline and 3 months in NAWM and thalami were nonsig-
nificant between NEDA groups (NAWM baseline: mean dif-
ference5 0.013ml/100g/min, 95% CI520.04 to 0.07,
p5 0.62; thalamus baseline: mean difference5 0.02ml/
100g/min, 95% CI520.03 to 0.07, p5 0.39; NAWM at
3 months: mean difference5 0.016ml/100g/min, 95%
CI520.03 to 0.06, p5 0.45; thalamus at 3 months: mean
difference5 0.02ml/100g/min, 95% CI520.02 to 0.06,
p5 0.25); thalamic Ki at 6 months showed an insignificant
trend for higher values (mean difference5 0.043ml/100g/
min, 95% CI5 0.002–0.09, p5 0.040) in the loss of
NEDA status group. In subjects who lost NEDA status at 1
year, only ARR 1 year pretreatment was significantly higher
(mean difference5 0.99, 95% CI5 0.42–1.56, p5 0.001).
An ROC curve with loss of NEDA at 2 years as outcome
showed that Ki in NAWM at 6 months was a good predictor
of loss of NEDA status at 2 years, with an AUC of 0.84
(95% CI5 0.70–0.99, p5 0.003; Fig 6). The optimal
threshold, defined as the value that provided the highest
FIGURE 4: Ki in periventricular normal-appearing white mat-
ter (NAWM) during the course of second-line treatment for
subjects who completed all 3 visits (n527). Bold lines rep-
resent mean Ki according to which treatment the subjects
received prior to second-line treatment (solid gray5no
prior treatment, black5 interferon beta [IFN-Beta] or glatir-
amer acetate [GA], dashed gray5methylprednisolone
within the past 2 months). Baseline scan was conducted
shortly prior to second-line treatment initiation, and follow-
up scans were conducted at 3 and 6 months after second-
line treatment. Error bars represent61 standard error of
the mean. [Color figure can be viewed at www.annalsof-
neurology.org]
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TABLE 1. Demographical, Clinical, and Ki Values according to NEDA Status 2 Years after Second-Line
Treatment
Characteristic
NEDA Status at 2 Years
p
Lost, n5 15 Maintained, n5 20
Age, yr 36 (8.2) 43.1 (9.9) 0.03a
Female gender, n 9 (60%) 14 (70%) 0.72b
EDSS score at baseline 2.5 (1.6) 3.2 (1.4) 0.17a
Disease duration, yr 4.7 (3.7) 8.1 (6.8) 0.09a
Number of relapses 1 year before treatment start 2.1 (0.9) 1.2 (0.7) 0.002a,c
Last relapse onset, days 150 (124) 137 (110) 0.75a
Relapse within 3 months from baseline 8 (53%) 12 (60%) 0.74b
Baseline treatment 1.00d
None 3 (20%) 5 (25%)
Interferon-b 10 (67%) 13 (65%)
Glatiramer acetate 2 (13%) 2 (10%)
Methylprednisolone< 2 months 4 (27%) 4 (20%) 0.70b
Days since treatment ende 27 (23) 39 (29) 0.80a
Baseline MRI
T2 lesion count 19.1 (12.7) 14.7 (8.5) 0.56
f
T2 lesion volume, mm
3 14.5 (15.2) 8.3 (3.5) 0.30f
1 Gd1 lesion 5 (33%) 5 (25%) 1.00b
Second-line treatment type5 natalizumab 5 (33%) 6 (30%) 1.00b
Ki NAWM, ml/100g/min
Baseline, n5 35 0.148 (0.078) 0.135 (0.072) 0.62a
Size, voxels 163 (92) 181 (102) 0.59a
3 months, n5 35 0.144 (0.049) 0.129 (0.062) 0.45a
Size, voxels 152 (92) 161 (83) 0.76a
6 months, n5 28 0.166 (0.059) 0.110 (0.029) 0.002a,c
Size, voxels 170 (99) 179 (86) 0.77a
Ki THAL, ml/100g/min
Baseline, n5 35 0.152 (0.082) 0.131 (0.057) 0.39a
Size, voxels 129 (59) 110 (51) 0.31a
3 months, n5 35 0.143 (0.042) 0.125 (0.054) 0.25a
Size, voxels 115 (43) 130 (46) 0.33a
6 months, n5 28 0.165 (0.069) 0.122 (0.037) 0.04a
Size, voxels 143 (50) 136 (47) 0.67a
Values are mean6 standard deviation. Ki at 6 months and number of relapses before treatment start were significantly higher in subjects with loss
of NEDA status at 2 years. Ki in thalamus at 6 months showed a trend for higher values but was nonsignificant.
aStudent t test.
bChi-square.
cStatistically significant.
dChi-square with first-line treatment yes/no.
eOnly entered for subjects who received steroid treatment within the past 2 months.
fStudent t test on log-transformed data.
EDSS5Expanded Disability Status Scale; Gd15Gadolinium enhancing lesion(s); MRI5magnetic resonance imaging; NAWM5 normal-
appearing white matter; NEDA5 no evidence of disease activity; THAL5 thalamus.
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added sensitivity and specificity34 of Ki in NAWM for
detecting loss of NEDA, was 0.136ml/100g/min, providing
a sensitivity of 73% and specificity of 82%. More than 1
annual relapse 1 year pretreatment predicted loss of NEDA
(AUC5 0.79, 95% CI5 0.64–0.94, p5 0.004) with a
sensitivity of 87% and specificity of 65%. Univariate logistic
regression analysis showed that Ki in NAWM at 6 months
was associated with loss of NEDA at 2 years (an increase of 1
SD [0.05ml/100g/min] with an odds ratio [OR]5 10,4
95% CI5 1.4–74, p5 0.02), as was number of annual
relapses 1 year pretreatment (OR5 9.2, 95% CI5 1.8–48,
p5 0.009), but not presence of active T2 lesions at 6
months, Ki in NAWM at 3 months, Ki in thalamus at 3 or 6
months, age, gender, MS years, EDSS, baseline lesion count,
or baseline contrast-enhancing lesions. Multivariate analysis
with all the above-mentioned covariates showed that Ki in
NAWM> 0.136ml/100g/min yielded an OR of 12.4 for
loss of NEDA at 2 years, whereas> 1 annual relapse 1 year
pretreatment was insignificant (Table 2). Two subjects
switched to other therapies after 5 and 8 months, possibly
influencing the NEDA outcome at 2 years. These were
included in the primary analysis if they were on treatment
while Ki was measured. Excluding these 2 subjects from the
ROC curve analysis of Ki in NAWM at 6 months, with
NEDA at 2 years as outcome, only caused minor changes to
the results (AUC5 0.84, 95% CI5 0.70–0.99, p5 0.003,
sensitivity 73%, specificity 81%).
DCE-MRI versus Conventional Contrast Imaging
Ten of 35 subjects (29%) had 1 or more contrast-
enhancing lesions on baseline MRI, and although these
FIGURE 5: Ki in periventricular normal-appearing white mat-
ter (NAWM; top) and thalamus (bottom) before natalizumab
or fingolimod treatment (baseline) and 3 and 6 months
posttreatment. Horizontal dotted lines represent optimal
threshold for loss of no evidence of disease activity (NEDA)
status from the receiver operating characteristic curve anal-
ysis. Black line represents mean Ki in subjects with main-
tained NEDA status at 2 years, and gray line represents
mean Ki in subjects with lost NEDA status. Error bars
represent61 standard error of the mean. [Color figure can
be viewed at www.annalsofneurology.org]
FIGURE 6: Result of receiver operator characteristic (ROC)
curve analysis with loss of no evidence of disease activity
status as outcome variable. Solid black line5Ki in normal-
appearing white matter at 6 months; dashed black line5Ki
in thalamus at 6 months; solid white line5annual relapse
rate 1 year prior to treatment start; dashed white line5new
active T2 lesions at 6 months. [Color figure can be viewed
at www.annalsofneurology.org]
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subjects had higher mean values of Ki at baseline (NAWM,
0.15ml/100g/min; thalami, 0.15ml/100g/min), the differ-
ence was not significant when compared to subjects with-
out contrast-enhancing lesions (NAWM, 0.14ml/100g/
min; thalami, 0.14ml/100g/min; mean difference:
NAWM, 0.01ml/100g/min, 95% CI5 –0.05 to 0.07;
thalamus, 0.01ml/100g/min, 95% CI520.03 to 0.05).
Only 2 subjects had contrast-enhancing lesions on the 3-
month follow-up MRI, and no subjects showed contrast
enhancement at the 6-month follow-up. We found no cor-
relation between gadolinium-enhancing lesions at baseline
and permeability at baseline, 3 months, or 6 months.
Discussion
Mechanistic Insights
This study enables investigation of the mechanistic rela-
tionship between Ki (as measured by DCE-MRI) and
cellular trafficking, by manipulation with disease-
modifying treatments, which decrease cellular traffic
across the BBB. We have previously found a correlation
between Ki and cellular traffic into the CSF, and absence
of correlation between Ki and albumin quotient, perhaps
suggesting that Ki may be a surrogate marker of cellular
influx.17 This study addresses this issue, because the
subjects maintaining NEDA represent an experimental
situation where cellular traffic has been inhibited phar-
macologically. We observe an apparent delay in the effect
on Ki such that 6-month but not 3-month Ki predicted
NEDA after 2 years. This lag is suggestive of an indirect
process as opposed to an immediate effect of decreased
cellular influx on Ki—which could reflect healing of the
BBB solute barrier in the first 3 months after initiation
of treatment. In those losing NEDA, one can hypothesize
ongoing damage to the BBB. Hence, the association
between cellular traffic and Ki may not be direct, but
more likely represents a sequence of events where changes
in cellular influx predate changes in the physical integrity
of the BBB solute barrier. Hence, solute BBB permeabil-
ity appears to be a prognostic marker, by reflecting the
"state of health" of the BBB. This study illustrates, in
vivo, the fundamental difference between cellular and
solute traffic in man. Dissociation between cellular traffic
and solute permeability has been observed in vitro, where
interferon beta reduces lymphocyte transmigration, while
having no effect on the permeability to albumin.35
We have previously reported that a Ki> 0.13ml/
100g/min identifies optic neuritis subjects with high risk
of conversion to RRMS, adding significant value
TABLE 2. Results of Stepwise Multivariate Logistic Regression with Loss of NEDA Status within the First 2
Years of Second-Line Treatment as Outcome Variable
Variable Optimal Cutoffa Predicted, nb Observed,
n (% correct)
p Odds Ratio 95% CI
Ki in NAWM 6 months
posttreatment
>0.136ml/100g/min 8 positives 11 (73%) 0.007 12.4 2 – 77
14 negatives 17 (82%)
Ki in the thalamus 6 months
posttreatment
>0.124ml/100g/min 9 positives 11 (82%) 0.10 — —
11 negatives 17 (65%)
Number of relapses 1 year
before treatment start
>1 13 positives 15 (87%) 0.07 — —
13 negatives 20 (65%)
Baseline T2 lesion count >13 10 positives 15 (67%) 0.94 — —
12 negatives 20 (60%)
Active T2 lesions at 6 months >0 2 positives 11 (18%) 0.06 — —
18 negatives 18 (100%)
Model Nagelkerke R25 0.37, p5 0.003. Ki in NAWM and thalamus are significant predictors of loss of NEDA status at 2 years. Number of relap-
ses 1 year before treatment start showed a trend but was nonsignificant.
aFrom receiver operating characteristic curve analysis.
bPredicted loss of NEDA status.
CI5 confidence interval; NAWM5 normal-appearing white matter; NEDA5 no evidence of disease activity.
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compared to using T2 lesions alone.17 It is very interest-
ing to note that the ROC threshold for further disease
activity is identical in clinically isolated syndrome17 ver-
sus established RRMS. This solute BBB permeability
threshold could act as a reproducible surrogate marker
for a BBB state associated with active disease.
Prediction of 2-Year NEDA Status
We also report the novel finding that a single measure-
ment of BBB permeability in NAWM performed 6
months after initiation of natalizumab or fingolimod is
capable of predicting loss of NEDA status within the
first 2 years of treatment. Because NEDA at 2 years has
recently been shown to predict disability progression as
measured by EDSS at 7 years nearly as well as NEDA at
5 years,11 measurements of BBB permeability could pro-
vide pivotal clinical information on treatment effect in
the individual patient and possibly even provide long-
term prognostic information. To our knowledge, no cur-
rent method is capable of comparable stratification of
treatment response to natalizumab or fingolimod. We
find that Ki in NAWM> 0.136ml/100g/min predicts
loss of NEDA at 2 years (OR5 12.4). For
comparison, 2 contrast-enhancing lesions in the first
year of treatment with interferon beta-1a identifies peo-
ple at high risk of disability progression 15 years later.
The OR for this effect was 8.9, one of the highest
reported in the MS prediction literature.36
Presence of visibly contrast-enhancing lesions was
not a significant determinant of Ki in NAWM or thalamus
at baseline, 3 months, or 6 months. Furthermore, Ki in
NAWM and thalamus was highly correlated in the same
subjects at baseline (Spearman CC5 0.86), 3 months
(CC5 0.88), and 6 months (CC5 0.82). Thus, the pre-
dictive effect of Ki is unlikely to be a carryover from the
prognostic effect of contrast-enhancing lesions or a result
of spillover of contrast agent from enhancing lesions into
the surrounding NAWM. Assuming a textbook value of
water diffusion in brain tissue of 1.03 1029m2/s,37 the
distance a water molecule that has been in contact with
contrast agent can diffuse during our DCE acquisition of
15 minutes is 1029m2/153 605 0.95mm. Thus, it is
highly unlikely that water from a gadolinium-enhancing
lesion would diffuse into our NAWM ROIs. However, one
study found contrast-enhancing lesions in the first year of
natalizumab treatment to predict future disease progres-
sion.38 In our cohort, contrast-enhancing lesions were only
seen in 2 subjects at 3 months and none was observed at 6
months or at 1 year. Despite this, Ki at 6 months predicted
NEDA at 2 years. This highlights the value of DCE-MRI
in the detection of diffuse low-level BBB leakage, as dis-
tinct from the focal high-level leakage detected by
conventional contrast MRI, most likely reflecting the dif-
ferent pathological processes in MS lesions and NAWM.
The acute MS lesion is characterized by demyelination,
axonal damage, gliosis, lymphocyte and macrophage infil-
trates, and focal BBB damage, whereas NAWM, despite
retaining myelin, often exhibits axonal swelling, activated
major histocompatibility complex II1 microglia and mac-
rophages, gliosis, increased expression of proteolytic
enzymes, and diffuse vessel leakage.39–41 DCE-MRI has
the additional advantage of using a lower dose of gadolin-
ium contrast compared to conventional contrast MRI.
Subjects with loss of NEDA at 2 years had signifi-
cantly more relapses in the year preceding treatment ini-
tiation. However, baseline ARR and lesion count are not
significant in the regression analysis of Ki on NEDA;
there is no correlation between 6-month Ki and days
since last relapse or baseline contrast-enhancing lesion
count; we only observed 1 relapse in close proximity to
the 6-month scan. This dispels the possibility that the
predictive effect of the higher Ki at 6 months on 2-year
NEDA is a throwback to higher baseline disease activity.
Possible Reasons for Treatment Failure
We found that Ki> 0.136ml/100g/min predicts subopti-
mal natalizumab or fingolimod treatment response with
a sensitivity of 73% and specificity of 81%. Possible rea-
sons for treatment failure include: (1) lack of compliance,
(2) neutralizing antibodies, (3) uncoupling of the disease
process from the drug’s mechanism of action, and (4)
high intrinsic disease activity. Lack of compliance and
neutralizing antibodies were excluded in this study,
because patients were monitored for both. Uncoupling of
disease and drug mechanism of action may occur if the
inflammatory process is self-driven within the brain or
alternative pathways have developed that allow persistent
encephalitogenic leucocyte entry into the brain, for
instance, higher expression of human leucocyte antigen I,
chemokines, and selectin ligands at the BBB and/or
structurally damaged endothelium. When treatment fail-
ure is due to high intrinsic disease activity, the drug is
effective at its target but the individual’s disease is so
active that the therapeutic effect is not enough and dis-
ease activity breaks through.
Ki Response
In our general linear model, we find a trend toward an
interaction effect of time and baseline methylpredniso-
lone treatment, indicating a treatment effect between
paired baseline and 6-month Ki only if baseline methyl-
prednisolone is accounted for. This is indicative of a
cumulative “Ki response” to both types of treatment, that
is, a decrease in Ki at baseline due to methylprednisolone
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and a decrease in Ki during the course of treatment with
fingolimod or natalizumab. Taken together, this indicates
that Ki response may provide a measure of treatment
response. To further elucidate this relationship, one
would need to follow individual patients over the course
of several treatment regimes, encompassing both subopti-
mal and optimal treatment responses in the same
individuals.
Proportion of NEDA
In this study, the proportion of subjects with loss of
NEDA status was 34% during the first year and 43%
during the second year. One natalizumab study reported
loss of NEDA status at 2 years in 38% of subjects, but
that study used less stringent MRI criteria not including
enlarging T2 lesions.42 In the AFFIRM trial, 63% had
lost NEDA status after 2 years of natalizumab treatment,
using the same NEDA criteria as in our study.19 A head-
to-head comparison of NEDA in natalizumab versus fin-
golimod treatment showed loss of NEDA status at 2
years in 30% and 77%, respectively.43 The large discrep-
ancy in the proportion of subjects with loss of NEDA
status could likely represent differences in patient selec-
tion. In clinical trials, subjects with highly active disease
are often favored for inclusion, to show maximum effect
of the treatment, whereas in this study we included all
patients starting on natalizumab or fingolimod treatment
during the given time window.
Permeability Changes in the Context of
Natalizumab or Fingolimod Treatment
Soon et al investigated T1-weighted signal intensity
changes after gadolinium–diethylenetriamine penta-acetic
acid administration in 27 RRMS patients after 24 weeks
on natalizumab treatment but found no effect of treat-
ment on signal change in NAWM when compared to 13
patients receiving placebo.44 No clinical parameters, such
as recent methylprednisolone treatment, relapses, and
individual treatment effect, were taken into account;
these are variables that we have shown govern Ki. This
emphasizes the importance of including clinical covariates
when characterizing changes in Ki over time.
Solute permeability across the BBB, which is
mainly governed by diffusion,45,46 is not synonymous
with T-cell migration across the BBB, which is a highly
regulated receptor-mediated process. To assess BBB per-
meability in this study, we used a macrocyclic gadolinium
chelate (gadobutrol; Gd-BT-DO3A), which is a 547Da
highly hydrophilic molecule.47 Thus, even though natali-
zumab blockage of the VLA-4 receptor results in reduced
migration of T-cells across the BBB, this does not neces-
sarily imply a change in solute permeability per se.45,46,48
The time delay observed in this study of the effect
of treatment on Ki, and the lack of correlation between
baseline visibly contrast-enhancing lesions and Ki at any
time point, indicate that solute permeability in NAWM
is secondarily modulated by a treatment-related reduction
of low-grade inflammatory activity. In summary, we find
that a single DCE-MRI at 6 months after initiation of
natalizumab or fingolimod treatment provides informa-
tion on the state of health of the BBB that enables reli-
able stratification of treatment response. Thus, DCE-
MRI can enable early detection of long-term suboptimal
treatment response in RRMS and a personalized medi-
cine approach to treatment, a limitation being the long
scan time (15 minutes). These results and the proposed
thresholds require validation in larger studies.
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